University of Groningen

Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184] (S0928098718300071) (10.1016/j.ejps.2018.01.007))

Notenboom, Sylvia; Weigand, Karl M.; Proost, Johannes H.; van Lipzig, Marola M.; van de Steeg, Evita; van den Broek, Petra H.H.; Greupink, Rick; Russel, Frans G.M.; Groothuis, Geny M.M.

Published in:

European Journal of Pharmaceutical Sciences

DOI:

[10.1016/j.ejps.2018.04.005](https://doi.org/10.1016/j.ejps.2018.04.005)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Notenboom, S., Weigand, K. M., Proost, J. H., van Lipzig, M. M., van de Steeg, E., van den Broek, P. H. H., Greupink, R., Russel, F. G. M., & Groothuis, G. M. M. (2018). Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184] (S0928098718300071) (10.1016/j.ejps.2018.01.007)). *European Journal of Pharmaceutical Sciences*, 117, 392-393. <https://doi.org/10.1016/j.ejps.2018.04.005>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184]

Sylvia Notenboom^{a,1}, Karl M. Weigand^{b,1}, Johannes H. Proost^a, Marola M. van Lipzig^c, Evita van de Steeg^c, Petra H.H. van den Broek^b, Rick Greupink^b, Frans G.M. Russel^b, Geny M.M. Groothuis^{a,*}

^a Pharmacokinetics, Toxicology and Targeting, Department of Pharmacy, University of Groningen, Groningen, the Netherlands

^b Department of Pharmacology and Toxicology, Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands

^c TNO (Netherlands Organization for Applied Scientific Research), the Netherlands

The authors regret the molar unit is incorrectly displayed on the x-axis in Fig. 4A and 4C and on the y-axis in Fig. 4B, 4D and Fig. 5. The correct versions of the figures are displayed below together with the

unchanged legends.

The authors would like to apologise for any inconvenience caused.
DOI of original article: 10.1016/j.ejps.2018.01.007

Fig. 4. The predicted intracellular concentrations (A) and canalicular efflux rates (B) of bile acids in the human hepatocyte following exposure to 60 μM bile acids on the portal side. The black dotted line in 3B represents the uptake rate of total bile acids (TBA) by NTCP, showing that uptake > efflux (B). After fitting the model to intracellular bile acid concentrations within the physiological range as measured by Starokozhko et al. and canalicular efflux rates (D) of bile acids in the human hepatocyte following 60 μM bile acids exposure on the portal side.

DOI of original article: <http://dx.doi.org/10.1016/j.ejps.2018.01.007>

* Correspondence to: Pharmacokinetics, Toxicology and Targeting, Department of Pharmacy, University of Groningen, the Netherlands.

¹ Sylvia Notenboom and Karl M. Weigand contributed equally to the work described in this manuscript

E-mail address: g.m.m.groothuis@rug.nl (G.M.M. Groothuis).

<https://doi.org/10.1016/j.ejps.2018.04.005>

Fig. 5. The predicted intracellular concentrations of bile acids in the human hepatocyte following exposure to 60 μM bile acids on the portal side in the absence (A) and presence of 6.6 μM cyclosporin A (B), 0.02 μM glibenclamide (C) and 20 μM glibenclamide (D).